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Abstract
Background: Lymphedema is a prevalent long-term effect of breast cancer treatment that is associated with
reduced quality of life. More recent observational data suggest that the addition of night-time compression to
day-time use of a compression garment results in better long-term control of arm lymphedema. The primary
objectives of the randomized controlled phase of the trial are to determine the efficacy of night-time compression on
arm lymphedema volume maintenance and quality of life in breast cancer survivors who have completed intensive
reduction treatment for their lymphedema.
Methods/Design: The study will be a parallel 3-arm, multi-centre randomized fast-track trial. A total of 120 women
with breast cancer related lymphedema will be recruited from 3 centres in Canada and randomized to group 1:
Day-time compression garment alone or Group 2: Day-time compression garment + night-time compression
bandaging or Group 3: Day-time compression garment + use of a night-time compression system garment. The
duration of the primary intervention period will be 12 weeks. The follow-up period after the intervention (weeks
13 to 24) will follow a longitudinal observational design. The primary outcome variables: differences from baseline
to week 12 in arm volume and quality of life (Lymphoedema Functioning, Disability and Health Questionnaire:
Lymph-ICF). Secondary outcomes include bioimpedance analysis, sleep disturbance and self-efficacy. All
measurements are standardized and will be performed prior to randomization, and at weeks 6, 12, 18 and 24.
Discussion: The use of night-time compression as a self-management strategy for chronic breast cancer
related lymphedema is seen as an innovative approach to improve long-term control over the condition. This
trial aims to advance the knowledge on self-management strategies for lymphedema.
Trial registration: This trial was registered at clinicaltrials.gov on July 9th, 2014 (NCT02187289)
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Background
Breast cancer is the most common cause of cancer in
Canadian women with an estimated 25,000 developing
the disease in 2015 [1]. With a current 5-year survival
rate of 88 %, a substantial number of women in Canada
are living with a history of breast cancer [1]. One of the
more frequent complications following treatment for
breast cancer is lymphedema, a significant swelling of
the arm that occurs on the surgical side. Lymphedema is
a lifelong condition that tends to worsen over time [2].
Recent data suggest that approximately 21 % of women
who undergo treatment for their breast cancer are diag-
nosed with lymphedema [3]. Of these cases, approximately
half will develop chronic progressive lymphedema [4, 5].
The impact of lymphedema on the breast cancer sur-
vivor is often profound, resulting in negative changes in
self-image, increased anxiety, and poorer quality of life
[6, 7]. Overtime, lymphedema can create considerable
disability with recurrent infections in the limb, func-
tional impairment, and pain [2, 8]. Many survivors see
lymphedema as an ongoing reminder of cancer to them-
selves, friends, and family [6]. Compounding the prob-
lem is that survivors report receiving limited support
and inadequate or conflicting information on the condi-
tion and its treatment from healthcare providers [6]. In a
matched cohort analysis of breast cancer survivors with
and without lymphedema, those with lymphedema had
significantly higher medical costs at 2 years (range of
$14,877 to $23,167) and were twice as likely to develop
an infection in the limb as compared to survivors with-
out lymphedema [8].
At present, there are no known curative treatments,
either surgical or pharmacological, for lymphedema [9].
Rehabilitative treatments, also called conservative treat-
ments, are prescribed to reduce and maintain limb size,
to restore function, to reduce pain, and to improve the
appearance of the limb [9, 10]. An initial intensive treat-
ment program is usually prescribed to reduce the lymph-
edema (Phase I) and is followed by a maintenance phase
(Phase II) which aims to promote life-long maintenance
[11]. Decongestive Lymphatic Therapy (DLT) is a 2-to-
4 week intensive treatment program comprised of daily
manual lymph drainage (MLD) massage (a specialized
massage technique), wrapping with multi-layered short-
stretch compression bandages (worn 23 h per day), ex-
ercise, and education [12]. The current recommended
intensive treatment approach for Phase I is DLT, with
or without the inclusion of the MLD massage compo-
nent [9]. Following treatment to reduce the swelling, a
compression sleeve is prescribed. Compression sleeves
represent current standard of care in lymphedema
maintenance (Phase II) [9].
A prospective cohort study including 682 women with
breast cancer related lymphedema examined the ability
of women to maintain arm lymphedema volume following
an intensive course of reduction treatment for lymph-
edema [13]. In the study, the authors observed a gradual
increase in lymphedema volume over time among study
participants, with the greatest increases seen in the first
year. The risk of treatment failure, defined as a >50 %
relapse in arm lymphedema volume from baseline levels,
was 38.1 %, 53.1 %, and 64.8 % at 1, 2, and 4 years respect-
ively [13]. Interestingly, women who wore a day-time
compression sleeve and also wrapped their affected limbs
with compression bandages (CB) at night (a minimum of
4 nights per week), had a significantly reduced risk of
relapse in arm lymphedema volume [hazard ratio, 0.53,
(0.34–0.82), P = 0.004] [13]. The authors concluded that
successful control of lymphedema may be dependent on
the combined use of the compression sleeve and CB
during day and night periods, respectively.
Applying compression at night is an option that is usually
presented to the survivor when the condition is advanced
or when relapses in symptoms and/or arm lymphedema
volume occur [9]. When night-time compression is indi-
cated, the survivor is taught how to apply the bandages to
the arm [Fig. 1]. Although many survivors are able to
bandage their arm independently, a family member or
significant other is often taught the bandaging tech-
nique and assists the survivor at night. Various types of
night-time compression system garments (NCSGs) have
been designed as alternatives to CB. NCSGs are simple
Fig. 1 Compression bandaging
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to use, quick to apply to the limb, and can be easily
adjusted to provide the appropriate amount of pressure.
In general, these compression system garments apply
gentle gradient pressure to the limb through a garment
with a foam liner and a series of adjustable straps
[Fig. 2]. The garments are non-elastic and provide low
resting pressure on the limb, making them safe to wear
while sleeping at night. NCSGs provide an alternative
self-management strategy for women to reduce the
time burden associated with compression bandaging as
well as for those unable to appropriately apply CB to
their arm (e.g., older individuals with mobility issues
and/or those who live alone). Although NCSGs are
already available for purchase, as with many marketed
treatment options for lymphedema, little is known
about their effectiveness.
Hypotheses of randomized controlled trial (Phase I)
1. Standard care plus the addition of CB will provide
statistically significant improved management of
arm lymphedema volume compared to standard
care alone at 12-weeks.
2. Standard care plus the addition of NCSG will
provide statistically significant improved
management of arm lymphedema volume
compared to standard care alone at 12-weeks.
3. Standard care plus the addition of NCSG will
provide statistically significant benefit in quality of
life, sleep and self-efficacy over standard care plus
CB and standard care alone at 12-weeks.
Objectives
The primary objectives of the randomized controlled
phase of the trial are to determine the effect of night-
time compression on arm lymphedema volume mainten-
ance and quality of life in breast cancer survivors who
have completed intensive reduction treatment for their
lymphedema. These questions are seen as valuable for
informing implementation of night-time compression as
a self-management strategy for lymphedema in the clin-
ical setting. The primary objectives of follow-up are to
evaluate the long-term adherence to use of night-time
compression and the timing of the intervention effect.
As well, this follow-up period will allow us to better
understand who may benefit the most (or least) from
the addition of night-time compression.
Methods/Design
The study will be a parallel 3-arm, multi-centre random-
ized fast-track trial including the Cross Cancer Institute
(CCI) in Edmonton, Tom Baker Cancer Centre (TBCC)
in Calgary and Mount St. Joseph’s Hospital (MSJ) in
Vancouver. Women enrolled in the study will be stratified
by accruing centre (CCI, TBCC, MSJ) and by lymphedema
severity (i.e., mild versus moderate lymphedema as per the
classification criteria of International Society of Lymphol-
ogy) [9, 14], and then randomly assigned to one of three
groups: (1) standard care (day-time use of a compression
sleeve alone); (2) standard care plus night-time compres-
sion by self-administered or assisted CB; (3) standard
care plus night-time compression by a traditional NCSG.
The duration of the primary intervention period will be
12 weeks. Results from the pilot study and previous case
studies suggest a small initial reduction in arm lymph-
edema volume from administration of the traditional
strapped NCSG over the first 6 weeks with stabilization of
arm volume (plateau) occurring thereafter. Thus, the
12-week intervention period is deemed sufficient to ob-
serve an intervention effect and was chosen to align
with current clinical follow-up time periods. Following
the 12-week intervention period, participants in the CB
and standard care groups will be measured for a NCSG.
Participants in these two groups will follow the proto-
col as per the NCSG group during weeks 13 to 24
[Fig. 3].
The randomized fast-track trial (with delayed assign-
ment to NCSG for both comparison groups) is seen as a
more acceptable design to patients, families and staff,
Fig. 2 Example of strapped version of a night-time compression
system garment
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given that the majority of eligible participants will have a
strong preference for assignment to the NCSG group.
Moreover, we feel this design, which was used in the
pilot study, will optimize recruitment and retention of
the comparison group participants in the trial.
The follow-up period after the intervention (weeks 13
to 24) will follow a longitudinal observational design and
provides an opportunity to examine factors related long-
term adherence to night-time compression.
Participants
The following eligibility criteria will be used to determine
participant inclusion in the trial:
1. Women with a histological diagnosis of breast
cancer experiencing lymphedema in the ipsilateral
arm such that there is a minimum 200 ml or 10 %,
and maximum 40 % increase in arm volume over
the unaffected arm (indicative of mild to moderate
lymphedema) [14].
2. Survivors must have completed all primary and
adjuvant cancer treatments (with the exception of
hormonal treatment) by a minimum of 1 month
prior to randomization.
3. Survivors must be in or entering the lymphedema
maintenance phase and agreeable to not pursuing any
other lymphedema maintenance treatments beyond
day-time use of a compression sleeve.
4. Survivors must have their own properly fitted
compression sleeve for day-time maintenance
and must agree to wear their day-time sleeve as
per standard care for a minimum of 12 h per
day.
5. No current use of night-time compression for
maintenance. Any survivor who has trialed a
NCSG/performed night-time CB in the past year for
maintenance purposes must observe a one-month
washout period before entering the trial.
Survivors will be excluded if they present with any of the
following
1. Clinical or radiological evidence of active breast
cancer, either local or metastatic.
2. History and clinical diagnosis of bilateral arm
lymphedema.
3. Serious non-malignant disease, such as renal or
cardiac failure, which would preclude daily
treatment and follow-up.
4. Survivors for whom compression is contraindicated,
such as those with untreated infections, skin
irritation/rash or thromboses in the affected arm.
5. Psychiatric or addictive disorders, as determined by
the referring physician, which preclude obtaining
informed consent or adherence to the protocol.
6. Unable to comply with the protocol, measurement,
and follow-up schedule due to factors, such as
vacation during the study period.
Interventions
Management in both the experimental and comparison
groups will follow recommendations of the Canadian
Fig. 3 Study schema
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Breast Cancer Initiative’s Steering Committee for Clinical
Practice Guidelines for the Care and Treatment of Breast
Cancer [15]. Survivors will be provided with advice con-
cerning good skin care, regular exercise, maintenance of a
healthy body weight, and the use of a day-time compres-
sion sleeve.
Group 1: standard care: day-time use of compression sleeve
alone
Women randomized to the standard care group will
receive standard care for lymphedema maintenance. In
this group of the trial, each participant will be instructed
to wear their day-time compression sleeve with or with-
out a gauntlet/glove (worn if swelling in the hand and
fingers), providing a minimum of 30 mm Hg of pressure,
for 12 h per day, each day of the week. A 6-week follow-
up will be performed to evaluate response and adherence
to the standard care protocol. At week 12, women in this
arm of the trial will be fitted for a NCSG and will follow
the protocol outlined in the experimental arm of the trial.
Group 2: standard care plus night-time multi-layered
Compression Bandaging (CB group)
Women randomized to the night-time CB group will be
instructed in the application of night-time multi-layered
CB by the physical therapist. Women who have per-
formed nighttime multi-layered CB as part of their past
maintenance program will attend a review session to en-
sure appropriate bandaging technique and application.
Educational materials related to compression bandaging
application will be provided. Participants will have a
2-week phase in period, following which they will be
asked to wear the CB at night while sleeping for a
minimum of 8 h per night, a minimum of five nights
per week for 4 weeks (weeks 3–6). As per standard of
care, each participant will be required to wear their
day-time compression sleeve with or without a gauntlet/
glove, providing a minimum of 30 mm Hg of pressure, for
12 h per day, each day of the week. A 6-week follow-up
will be performed to evaluate response and adherence to
the CB protocol. At that point, maintenance CB a mini-
mum of 3 times per week will be introduced. At week 12,
women in this arm of the trial will be fitted for a NCSG
and will follow the protocol outlined in the experimental
arm of the trial.
Group 3: standard care plus Night-Time Compression
System Garment (NCSG group)
Women randomized to the immediate NCSG group will
be measured for a NCSG. Once the garment has arrived,
participants in this group will be instructed in use of
their NCSG by the physical therapist. Educational mate-
rials related to garment application and maintenance will
be provided. Participants will have a 2-week phase in
period, following which they will be asked to wear the
NCSG at night while sleeping for a minimum of 8 h per
night, a minimum of five nights per week for 4 weeks
(weeks 3–6). As per standard of care, each participant
will be required to wear their day-time compression sleeve
with or without a glove/gauntlet, providing a minimum of
30 mm Hg of pressure, for 12 h per day, each day of the
week. A 6-week follow-up will be performed to evaluate
response, adherence to the protocol and to address any
issues with wear of the NCSG. At that point, maintenance
NCSG a minimum of 3 nights per week will be intro-
duced. After the 12-week assessment, participants in this
arm of the trial will have the option to continue use of
their NCSG.
Recruitment
Ethics approval and signed informed consent of partici-
pants is required. Recruitment started after approval was
received from all respective Health Research Ethics
Committees (Health Research Ethics Board of Alberta:
Cancer Committee and the University of British Columbia
Ethics Board). The estimated timeline for recruitment is
18–24 months. Potential participants will be identified
and screened for eligibility by the respective research coor-
dinators through the Rehabilitation Medicine Depart-
ments at the CCI in Edmonton, the TBCC in Calgary, and
MSJ in Vancouver. Initial eligibility will be determined by
chart review and, if necessary, verified through contact
with the participant’s physician. Interested participants
will be scheduled for a baseline visit to obtain written
consent and for final determination of eligibility. It is
anticipated that 10 to 15 breast cancer survivors with
lymphedema (per month) will be eligible among the three
centres and that 5–8 women (per month) will agree to
participate. Follow-up measurements will occur at week 6,
12 (end of RCT portion), 18, and 24 following the start of
the assigned intervention for the participant. The last
participant entering the trial will therefore undergo her
24-week follow-up measurement approximately 30 months
after recruitment begins.
Baseline data and endpoints
During the baseline visit, demographic and clinical infor-
mation will be collected on participants. Medical data
will be abstracted from the medical health records.
Primary endpoints
Arm volume is a commonly used metric to evaluate
lymphedema severity and to inform decision-making in
the clinical setting. Lymphedema will be objectively
measured using the Perometer (Pero-systems, Wipputal,
Germany). The Perometer is an optoelectric limb volume-
ter that uses infrared technology to quantify limb volume
and determine inter-limb difference. Measurement with
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the perometer takes approximately 3 min to complete.
The perometer is a valid, reliable, and sensitive method
for quantifying limb volume [16–18].
Quality of life will be measured using the condition-
specific Lymphoedema Functioning, Disability and Health
Questionnaire (Lymph-ICF) [19]. This 29-item question-
naire was developed to assess quality of life specific to
lymphedema and to monitor progress of treatment on
function (i.e., movement, activities) and symptoms related
to lymphedema (i.e., pain, discomfort, heaviness, and ten-
sion) as well as to assess activity limitations and participa-
tion restrictions. The Lymph-ICF has been tested and
shown to be valid and reliable [19]. As well, general
health-related quality of life will be assessed at each visit
by using the RAND 36-item Short Form Health Survey
(SF-36). These two questionnaires will take approximately
10–15 min to complete.
Secondary endpoints
Secondary endpoints will include bioimpedance analysis,
adherence, sleep disturbance, and self-efficacy.
Bioimpedance analysis (BIA) will be used to assess
extracellular fluid status within the arm. BIA measures
the impedance of flow from a low alternating electrical
current that is applied to the body through a skin elec-
trode. BIA records impedance values for each limb and
provides an index that correlates with quantitative mea-
surements of volume increase in limb size seen in the
arm with lymphedema [20]. BIA is a simple, painless
procedure that takes less than 5 min to perform. BIA
has been shown to be a more sensitive measure than
arm volume in detecting changes in lymphedema in
those with early mild lymphedema but less reliable in
those with long-standing lymphedema [20]. This meas-
urement will provide information on extracellular fluid
changes that complements the data on arm lymphedema
volume.
Sleep disturbance will be assessed using the RAND
Medical Outcomes Survey Sleep Survey [21]. The survey
measures 6 key dimensions of sleep: sleep initiation,
maintenance, quantity, adequacy, drowsiness, and respira-
tory impairments (e.g. shortness of breath, snoring). The
sleep scale will be used to assess the impact, if any, of
wearing night-time compression on sleep quality. The
questionnaire takes 5 min to complete.
Self-efficacy of lymphedema management
Self-efficacy will be assessed based on the 6-item Chronic
Disease Self-Management scale [22] modified for use with
lymphedema. The scale assesses several domains that are
common across chronic diseases such as symptom control,
role function, emotional functioning, and communicating
with physicians. The questionnaire takes 3-to-5 min to
complete.
Body height will be recorded at baseline and body
weight at baseline and each follow-up time point.
Adherence
Participants will be asked to record their adherence (i.e.
days per week, hours per day) to their assigned compres-
sion therapy treatment in a daily journal. Treatment-
specific outcomes such as the time required for adminis-
tration of night-time compression, reasons for removal
of the garment at night and independence/assistance in
application will be included in the diary. Participants will
be asked to return the completed diary for each respective
6-week time period at the subsequent follow-up visit. We
will also record any additional appointments required to
teach CB or to assess wear/fit of the NCSG.
Adverse events
Adverse events related to the application of compression
(i.e. skin breakdown or reaction, such as rash) will be
recorded. Any adverse events related to the condition of
lymphedema (i.e. infection/cellulitis or blood clot in the
arm) will be verified with the participant’s physician. If
this occurs, as per standard care, treatment with com-
pression will be stopped until deemed safe to resume by
the physician. We will also record any relapses in arm
lymphedema volume (>50 %) that require more intensive
reduction treatment.
Allocation concealment and method of randomization
Participants will be randomized in a 1:1:1 ratio to Standard
Care, CB or NCSG using a secure central randomization
service administered by the Clinical Trials Unit of the Cross
Cancer Institute.
Blinding
At each measurement point starting after the baseline
assessment through the RCT portion of the trial (i.e.,
6 week and 12 week follow-ups), an Independent Assessor
unaware of treatment allocation (blinded) will perform the
measurements of arm volume using the perometer, bioim-
pedance analysis, and body weight. The Independent
Assessor will also administer the outcome measures for
sleep disturbance, self-efficacy, and quality of life. The
Adherence Diary will be collected by the Research Coord-
inator at each follow-up visit. Follow-up sessions will take
place in the respective rehabilitation department and each
session will take 30 to 45 min to complete. Blinding of
participants and practitioners will not be possible as par-
ticipants are aware of the compression therapy treatment
they are receiving. Study garments will be purchased at
cost from participating industry partners through the
grant funds. In the event that a study participant is unable
to continue with their assigned treatment, they will re-
main in their randomized group to preserve the intention-
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to-treat principle. Study participants will be free to with-
draw at any time but will be invited to continue to attend
for scheduled follow-ups for the duration of the study.
Sample size for randomized fast-track trial phase
The sample size required per group to detect at least a
minimal clinically important mean difference of 20 %
(SD ±25) in arm lymphedema volume in favor of either
the standard care + NCSG, standard care + CB group
and standard care alone is 36 participants. A total sam-
ple of 108 participants will achieve a power of 86 % with
a significance level of 0.05 using a one way ANOVA test.
The sample size required per group to detect at least a
minimal clinically important difference on the Lymph-
ICF quality of life scale of 15 points out of 100 (SD ±22)
between the standard care + CB group and the standard
care + NCSG group is 36 participants. A total sample of
108 will achieve a power of 80 % with a significance level
of 0.05 using a two-sided Mann-Whitney test assuming
the actual distribution is normal. To allow for an estimated
10 % loss to follow-up and non-compliance/cross-over of
the standard care group, we will recruit an additional 12
patients for a total of 120 participants (40 participants in
each of the three treatment groups).
Statistical analyses
Baseline medical and demographic characteristics, arm
dominance relative to the lymphadematous arm, and
adverse events of the three groups will be compared
using one-way ANOVA for continuous data and Pear-
son’s Chi-square tests for categorical data. The primary
analysis will compare the groups with regard to percent
excess lymphedema volume and quality of life at 12-
weeks using a one-way ANOVA. General linear models
will be used to adjust for centre and lymphedema cat-
egory (mild or moderate), and to evaluate the treatment
effect in subgroups defined by the strata. Sleep quality,
self-efficacy, and adherence-related outcomes will be
analyzed by repeated measures modeling and one-way
ANOVA on change scores.
Descriptive data on accrual rates will include the num-
ber of women screened for eligibility, the number eligible,
the number agreeing to participate, and reasons for refusal
to participate. Data on adherence will be collected from
all women throughout the 24-week study period. Adher-
ence data will include days worn per week and hours worn
per 24-h period, as appropriate, for each of the following:
1) NCSG; 2) CB; 3) day-time compression sleeve. We will
also examine adherence during weeks 13 to 24 to the
newly assigned NCSG for the standard care and standard
care + CB groups, and ongoing adherence during weeks
13 to 24 in the originally assigned standard care +NCSG
group. Analyses of primary outcomes will be performed at
the end of the RCT portion of the trial. Within group
analyses will also be conducted for primary and secondary
outcomes from weeks 13 to 24 following completion of all
follow-up measures.
Trial management
A primary Trial Coordinator will be assigned by the
CTU for the Edmonton site and this individual will over-
see the day-to-day operations of the project and report
directly to Dr. McNeely. The primary Trial Coordinator
revised the standard operating procedures used in the
pilot study in consultation and in collaboration with the
research team members. The Calgary and Vancouver sites
have Research Coordinators/Physical Therapist (PT) who
work under the supervision of Drs. McNeely and Campbell,
respectively. The respective Research Coordinator-PT will
be responsible for booking of participant appointments,
teaching of self-bandaging to participants, measurement
and fitting of participants for night-time compression sys-
tem garments, and provide assistance and oversight for data
collection and data entry. Case report form development,
randomization, data entry, quality assurance and data ana-
lysis will be carried out by the CTU. To protect the identity
of study participants, forms will be labeled with the partici-
pant study identification number and initials only. Original
case report forms will be sent to the CTU. Copies of the
original forms will be secured in the respective depart-
ments. The CTU will provide biostatistical support for the
statistical analyses of data.
Discussion
Integrated knowledge translation
A survivor-representative, physical and occupational thera-
pists, rehabilitation department administrators, and indus-
try were asked to provide input on knowledge translation
goals and methods. Consumer interests include informa-
tion on the value of the garment for lymphedema, garment
choice and options and prescription variables (i.e. how
long to wear, how many nights per week). Goals of the
healthcare practitioners include understanding the rela-
tive benefit of NCSGs and resolving when to best prescribe
garments. Other questions revolve around independence
in application and time benefit for the survivor. In-
dustry interests include questions on NCSG comfort
and effectiveness.
Knowledge translation methods will include webinars,
workshops and small group face-to-face sessions for sur-
vivor groups in Alberta and British Columbia as well as
front-line health care practitioners working directly with
breast cancer survivors in these two provinces. Connec-
tions with Alberta’s Community Cancer Support Network,
Alberta CancerControl Supportive Care Council, British
Columbia Cancer Agency, the Alberta Lymphedema As-
sociation and the British Columbia Lymphedema Associ-
ation will ensure that information gained from the study
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will be delivered across the regions (i.e, newsletter and
email communications). Nationally, research findings
will be disseminated to the Canadian Physiotherapy As-
sociation Oncology Division (i.e. study briefing in news-
letter), and the Canadian Lymphedema Framework (i.e.,
lay language summary in lymphedema magazine
Pathways).
Limitations
Limitations of the current design include the requirement
that participants be able and willing to be randomized to
one of the three groups for a 12-week period. For this
reason, we anticipate women who regularly administer CB
at night and/or attend regular maintenance sessions of
MLD will not be interested, or eligible to take part in the
trial.
Progress to date
As of September 2015, 39 women with breast cancer
related lymphedema have been randomized and no
adverse events have occurred.
Relevance and innovation
As the numbers of survivors of breast cancer continues
to grow, there is need for supportive care interventions
to address the late and long-term effects of cancer treat-
ment. Lymphedema is a prevalent long-term effect of
treatment that is associated with reduced quality of life.
There are currently a number of products and devices
on the market purported to reduce and/or help manage
lymphedema, many of which can be purchased directly
by the survivor on the internet. However, there is a paucity
of quality research to support the use of many of these
products and interventions for lymphedema, including
NCSGs. For these reasons, healthcare practitioners are
unsure of how to best advise survivors. This study will
prospectively examine the effect of the addition of night-
time compression to current standard care on the quality
of life of breast cancer survivors with lymphedema. While
these treatment techniques have been used clinically for
many years, the evolution of night-time compression ther-
apy as a self-management strategy is the innovative aspect
of this approach and research. In this way, this study will
help advance the knowledge on self-management strat-
egies for lymphedema.
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